Vir Biotechnology (VIR) Operating Leases (2020 - 2026)

Vir Biotechnology's Operating Leases history runs 7 years deep, the most recent figure standing at $86.6 million for Q1 2026.

• In Q1 2026, Operating Leases fell 1.74% year-over-year to $86.6 million; the TTM figure through Mar 2026 stood at $86.6 million (down 1.74% YoY), while the FY2025 annual figure was $89.1 million, down 9.03% from the prior year.
• Operating Leases came in at $86.6 million for Q1 2026 at Vir Biotechnology, down from $89.1 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $132.8 million in Q1 2022 to a low of $86.6 million in Q1 2026.
• A 5-year average of $107.5 million and a median of $109.2 million in 2024 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases soared 99.37% in 2022 and slipped 19.35% in 2024, its largest moves.
• Vir Biotechnology's Operating Leases stood at $128.0 million in 2022, then dropped by 12.74% to $111.7 million in 2023, then declined by 12.34% to $97.9 million in 2024, then declined by 9.03% to $89.1 million in 2025, then slipped by 2.72% to $86.6 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $86.6 million, $89.1 million, and $91.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison